We are still waiting to hear data from cohort 3 and 4 of the GBM trial. Thats now gone to an expansion trial. So prob no updates until end of year into 1st quarter of next year.
The AML trial with NK has also been in stealth mode. This adding to it could mean its looking promising, or it could mean results werent as good as expected so they are trying patients at an earlier stage. The NK cells had provided a couple of CRs previously, so am thinking they had plenty of data prior to trial to know where the sweet spot should be. So maybe mid late next year for an update on this one.
Market cap at the moment isnt much more than the money in the bank. Spend is still large (as are all spends when trialing CarT drugs). But money in the bank should be enough to get to any pivot data point.
The market still doesn't like risk. So think the share price will stay low and flatbfor a while. But faur value would seem to be 10 to 15bags up from present market cap, considering pipeline development, when compared to some peers.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)